...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>International Journal of Molecular Sciences >Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children
【24h】

Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children

机译：药物遗传学在儿童造血干细胞移植结果中的作用

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Hematopoietic stem cell transplantation (HSCT) is an established therapeutic procedure for several congenital and acquired disorders, both malignant and nonmalignant. Despite the great improvements in HSCT clinical practices over the last few decades, complications, such as graft vs. host disease (GVHD) and sinusoidal obstructive syndrome (SOS), are still largely unpredictable and remain the major causes of morbidity and mortality. Both donor and patient genetic background might influence the success of bone marrow transplantation and could at least partially explain the inter-individual variability in HSCT outcome. This review summarizes some of the recent studies on candidate gene polymorphisms in HSCT, with particular reference to pediatric cohorts. The interest is especially focused on pharmacogenetic variants affecting myeloablative and immunosuppressive drugs, although genetic traits involved in SOS susceptibility and transplant-related mortality are also reviewed.
机译：造血干细胞移植（HSCT）是一种针对多种先天性和后天性疾病（恶性和非恶性）的公认治疗方法。尽管在过去的几十年中，HSCT临床实践取得了很大的进步，但是诸如移植物抗宿主病（GVHD）和窦性阻塞综合征（SOS）等并发症仍然很大程度上无法预测，仍然是发病率和死亡率的主要原因。供体和患者的遗传背景都可能影响骨髓移植的成功，并且至少可以部分解释HSCT结果的个体间差异。这篇综述总结了HSCT中候选基因多态性的一些最新研究，特别是儿科队列研究。尽管也对涉及SOS易感性和移植相关死亡率的遗传特征进行了研究，但人们的兴趣尤其集中在影响清髓和免疫抑制药物的药物遗传学变异上。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号